Exelixis Aktie - EXEL

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Premium

Current Price

33,97

Gebot

33,50

Fragen

34,55

Volumen

1.307.404

33,79 Tagesbereich 34,12

19,20 52-Wochen-Bereich 36,97

Marktkapitalisierung

9,701B

Handelsende

33,94

Handelsbeginn

33,79

Letzte Trade

33.6843

Letzter Handelszeitpunkt

Finanzvolumen

US$ 44.394.106

VWAP

33,9559

Durchschnittliches Volumen (3 Mio.)

2.273.725

Ausgegebene Aktien

285.579.020

Dividendenrendite

Kurs-Gewinn-Verhältnis

46,72

Gewinn pro Aktie (EPS)

0,73

Erlöse

1,83B

Nettogewinn

207,77M

Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under... Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma. Mehr anzeigen

Sektor

Biological Pds,ex Diagnstics

Branche

Biological Pds,ex Diagnstics

Website

www.exelixis.com

Hauptsitz

Wilmington, Delaware, USA

Gegründet

Exelixis Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker EXEL. The last closing price for Exelixis was US$33,94. Over the last year, Exelixis shares have traded in a share price range of US$ 19,20 to US$ 36,97.

Exelixis currently has 285.579.020 shares in issue. The market capitalisation of Exelixis is US$9,69 billion. Exelixis has a price to earnings ratio (PE ratio) of 46.72.

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in December

-- Presentations to be webcast on www.exelixis.com -- Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor...

Form 4 - Statement of changes in beneficial ownership of securities

Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors

Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib...

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0.07	0.206489675516	33.9	34.25	33.25	1450071	33.67444749	CS
4	-2.18	-6.03042876902	36.15	36.215	33.11	2008417	34.21034864	CS
12	8.21	31.8711180124	25.76	36.97	25.76	2273725	33.16143914	CS
26	11.81	53.2942238267	22.16	36.97	21.82	1967801	29.46416697	CS
52	10.12	42.4318658281	23.85	36.97	19.2	2061347	25.71535969	CS
156	15.74	86.341195831	18.23	36.97	14.87	2334034	21.1061271	CS
260	16.66	96.2449451184	17.31	36.97	13.67	2373564	21.10769812	CS

EXEL - Frequently Asked Questions (FAQ)

What is the current Exelixis share price?

The current share price of Exelixis is US$ 33,97

How many Exelixis shares are in issue?

Exelixis has 285.579.020 shares in issue

What is the market cap of Exelixis?

The market capitalisation of Exelixis is USD 9,69B

What is the 1 year trading range for Exelixis share price?

Exelixis has traded in the range of US$ 19,20 to US$ 36,97 during the past year

What is the PE ratio of Exelixis?

The price to earnings ratio of Exelixis is 46,72

What is the cash to sales ratio of Exelixis?

The cash to sales ratio of Exelixis is 5,3

What is the reporting currency for Exelixis?

Exelixis reports financial results in USD

What is the latest annual turnover for Exelixis?

The latest annual turnover of Exelixis is USD 1,83B

What is the latest annual profit for Exelixis?

The latest annual profit of Exelixis is USD 207,77M

What is the registered address of Exelixis?

The registered address for Exelixis is 251 LITTLE FALLS DRIVE, NEW CASTLE, WILMINGTON, DELAWARE, 19808

What is the Exelixis website address?

The website address for Exelixis is www.exelixis.com

Which industry sector does Exelixis operate in?

Exelixis operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
FCUVFocus Universal Inc	US$ 0,9499 (174,93%)	260,93M
NITON2OFF Inc	US$ 2,6306 (145,85%)	358,28M
CRNCCerence Inc	US$ 19,33 (143,76%)	161,8M
KITTNauticus Robotics Inc	US$ 3,8249 (140,56%)	104,8M
ACONAclarion Inc	US$ 0,2984 (110,14%)	305,64M
HWHHWH International Inc	US$ 0,4621 (-28,80%)	7,43M
SMSTDefiance Daily Target 2x Short MSTR ETF	US$ 5,69 (-26,30%)	24,77M
RAINRain Enhancement Technologies Holdco Inc	US$ 5,59 (-23,42%)	161,15k
PTLEPTL Ltd	US$ 9,35 (-23,30%)	1,04M
NXUNXU Inc	US$ 0,725868 (-22,78%)	7,59M
NITON2OFF Inc	US$ 2,6306 (145,85%)	358,28M
TGLTreasure Global Inc	US$ 0,382 (101,58%)	337,5M
ACONAclarion Inc	US$ 0,2984 (110,14%)	305,64M
FCUVFocus Universal Inc	US$ 0,9499 (174,93%)	260,93M
NVDANVIDIA Corporation	US$ 144,47 (4,45%)	230,01M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Exelixis Inc (EXEL) Börsenkurse

Exelixis Inc (EXEL)

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Wichtige Statistiken und Details

Über Exelixis Inc

EXEL Neueste Nachrichten

EXEL - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen